Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: A meta-analysis

Future Oncology

Volumn 11, Issue 21, 2015, Pages 2949-2961

  Abdel Rahman, Omar ^a   Elhalawani, Hesham ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

anemia; neutropenia; ramucirumab; thrombocytopenia

Indexed keywords

RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANEMIA; BREAST METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; COCHRANE LIBRARY; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; LEUKOPENIA; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS; METASTATIC COLORECTAL CANCER; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; COMPLICATION; HEMATOLOGIC DISEASES; NEOPLASMS; ODDS RATIO; RISK; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; NEOPLASMS; ODDS RATIO; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84946235122     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.178     Document Type: Review

References (42)

1. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52-79 (2015).
2. Zhang M-Y, Lu J-J, Wang L et al. Development of monoclonal antibodies in China: overview and prospects. Biomed. Res. Int. 2015, 168935 (2015).
3. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann. Transl. Med. 2(12), 123 (2014).
4. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (rainbow): a double-blind, randomised Phase 3 trial. Lancet Oncol. 15(11), 1224-1235 (2014).
5. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase 3 trial. Lancet 383(9911), 31-39 (2014).
6. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit. Rev. Oncol. Hematol. 93(1), 18-27 (2015).
7. Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev. Anticancer Ther. 14(9), 1063-1073 (2014).
8. Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Ramucirumab: preclinical research and clinical development. Onco. Targets Ther. 7, 1997 (2014).
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151(4), 264-269 (2009).
10. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177-188 (1986).
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 327(7414), 557 (2003).
12. Doebele RC, Spigel D, Tehfe M et al. Phase 2, randomized, open?label study of ramucirumab in combination with first?line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/ metastatic non-small cell lung cancer. Cancer 121(6), 883-892 (2015).
13. Yardley D, Richards P, Reeves J, Dees E, Osborne C, Soliman H. Final results of a Phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). J. Clin. Oncol. 32, s5 (2014).
14. Yoon HH, Bendell JC, Braiteh FS et al. Ramucirumab (RAM) plus folfox as front-line therapy (RX) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter Phase 2 trial. J. Clin. Oncol. 32, s5 (2014).
15. Clinical trials database: NCT01160744. https://clinicaltrials.gov
16. Zhu A, Ryoo B, Yen C et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: results from the randomized Phase III reach study. Presented at: ESMO Congress 2014. Madrid, Spain, 26-30 September 2014.
17. Garon EB, Ciuleanu T-E, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, doubleblind, randomised Phase 3 trial. Lancet 384(9944), 665-673 (2014).
18. Hussain M, Rathkopf DE, Liu G et al. A Phase ii randomized study of cixutumumab (IMC-A12: Cix) or ramucirumab (IMC-1121b: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (MCRPC) following disease progression (PD) on docetaxel (DCT) therapy. Presented at: ASCO Annual Meeting 2012. Chicago, IL, USA, 1-5 June 2012.
19. Mackey JR, Ramos-Vazquez M, Lipatov O et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled Phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J. Clin. Oncol. 33(2), 141-148 (2015).
20. Tabernero J, Cohn A, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu T. RAISE: a randomized, double-blind, multicenter Phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J. Clin. Oncol. 33, Abstract 512 (2015).
21. Abdel-Rahman O. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol. 35(11), 10615-10625 (2014).
22. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10(7), 505-514 (2010).
23. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit. Rev. Oncol. Hematol. 92(3), 194-207 (2014).
24. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev. Anticancer Ther. 15(1), 129-141 (2015).
25. Bozza C, Fontanella C, Buoro V, Mansutti M, Aprile G. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? Expert Rev. Clin. Pharmacol. 8(2), 251-265 (2014).
26. Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat. Rev. 39(7), 818-830 (2013).
27. Schutz FA, Jardim DL, Je Y, Choueiri TK. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur. J. Cancer 47(8), 1161-1174 (2011).
28. Zhou F, Shao J-H, Wu L-Q, Yin X-B, Yu X. Risk of serious neutropenic events in cancer patients treated with bevacizumab: a meta-analysis. Asian Pac. J. Cancer Prev. 14(4), 2453-2459 (2013).
29. Qi W-X, Fu S, Zhang Q, Guo X-M. Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials. Crit. Rev. Oncol. Hematol. 94(3), 323-336 (2015).
30. Sher A, Wu S. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-a meta-analysis. Acta Oncol. 50(7), 997-1005 (2011).
31. Schutz FA, Je Y, Choueiri TK. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a metaanalysis of clinical trials. Crit. Rev. Oncol. Hematol. 80(2), 291-300 (2011).
32. Kamba T, McDonald D. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96(12), 1788-1795 (2007).
33. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J. Clin. Oncol. 21(18), 3542-3542 (2003).
34. Van Der Veldt AA, Boven E, Vroling L, Broxterman HJ, Van Den Eertwegh AJ, Haanen JG. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J. Clin. Oncol. 27(8), 1339-1340 (2009).
35. Alexandrescu DT, Mcclure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J. Clin. Oncol. 26(24), 4047-4048 (2008).
36. Pessina A, Malerba I, Gribaldo L. Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Curr. Pharm. Des. 11(8), 1055-1065 (2005).
37. Gabbianelli M, Pelosi E, Montesoro E et al. Multi-level effects of FLT3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86(5), 1661-1670 (1995).
38. Kimura Y, Ding B, Imai N, Nolan DJ, Butler JM, Rafii S. C-KIT-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS ONE 6(10), e26918 (2011).
39. Weisel KC, Yildirim S, Schweikle E, Kanz L, Moehle R. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann. NY Acad. Sci. 1106(1), 190-196 (2007).
40. Rusten L, Lyman S, Veiby O, Jacobsen S. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood 87(4), 1317-1325 (1996).
41. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the FLK2/FLT3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3(1), 147-161 (1995).
42. Desch CE, Benson AB, Somerfield MR et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 23(33), 8512-8519 (2005).